Featured Articles From The Current Issue
PROTEIN THERAPEUTICS MARKET - Technology Advances Spur Market Growth of Protein Therapies
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.


>>> See All Cover Stories

Cai Xuan, PhD, and Volkan Gunduz, PhD, GlobalData Analysts, estimate that by the end of the forecast period in 2025, NSCLC sales will rise to $26.8B in the 8MM, at a moderate CAGR of 15.7%.
Mirco Junker, PhD, GlobalData Analyst, says high cure rates exceeding 90% are now achievable for most patients suffering from chronic hepatitis C, and as a result, the industry is reaching a new phase in the fight against this deadly infectious disease.
Michela J. McMullan, PhD, GlobalData Analyst, reports that although the ACS market is set to grow at a CAGR of 4.6%, reaching $12.1B by 2025, the potential for the market to be even more lucrative exists, especially in the sizable lipid-targeting arena.
Laurie L. Sullivan and John Bergin, MS, MBA, BCC Research Analysts, indicate that NGS has matured into an essential life science tool for genetic studies in a range of applications, and the industry is on the cusp of a second growth phase, powered by new applications in clinical diagnostics.
Michael Graffeo, Vice President of Business Development, Insulet Delivery Systems Group, discusses the importance of optimizing patient adherence to ensure improved clinical outcomes.
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
John A. Bermingham, asks if you have ever been really hungry? He doesn’t mean the hunger you experience in the morning or just before dinner. He’s talking about major league hunger!
Bill Welch says when developing a combination product, there are many things to be considered – relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding user needs, determining product requirements, as well as device manufacturing variation.
Michael D. Hooven, MSME, says the new, most advanced wearable large-volume injectors available now for clinical trials and commercial application are designed to address the challenges of formulating biologics, delivery complexity, patient compliance, and cost.
Eugene T. Polini, MBA, reviews how cryogenics has proven to be especially useful in the pharmaceutical industry, where cryogenic storage is being utilized to ensure the efficacy of advanced therapeutics, such as biologics and stem cell therapies.
John A. Merhige, MEM, and Lisa Caparra, RN, present an informative human factors study to evaluate and assess the intuitiveness, ergonomics, and usability of the Credence Companion® Staked Safety Syringe.
Wetteny Joseph, President of Clinical Supply Services at Catalent Pharma Solutions, discusses the changing nature of clinical trials and the supply of materials for studies, and how Catalent is investing in new solutions, systems, and facilities to assist the biopharmaceutical industry.

Exclusive Online Content
West Announces Expanded Contract Manufacturing Capabilities in IrelandWest Announces Expanded Contract Manufacturing Capabilities in Ireland
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced the completion of a 60,000 square foot expansion at its contract manufacturing facility near Mulhuddart, County Dublin.

Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline
Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, says business intelligence provider GBI Research.

Vetter: Choosing the Right Diluent to Help Maximize Success   Vetter: Choosing the Right Diluent to Help Maximize Success
The biologics market continues to rise, expecting to reach $250 billion by 2024. Due to the unstable nature and limited shelf life of many biopharmaceutical compounds, there is an increase in the demand for lyophilized drugs.

Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals
Ligand Pharmaceuticals Incorporated recently announced that partners Spectrum Pharmaceuticals (EVOMELA) and Lundbeck (CARNEVIX) received US FDA Approval.

Evonik Ramps Up Production Capacity for Biomaterials Evonik Ramps Up Production Capacity for Biomaterials
Evonik is expanding its production facilities to create additional capacity for the production of biodegradable polymers marketed globally under the brand names RESOMER® and RESOMER® SELECT.

MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell ImagingMilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
MilliporeSigma has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging to more effectively perform in-depth analysis of cellular mechanisms and behavior in a live environment.

Business Development Manager Needed at FarevaBusiness Development Manager Needed at Fareva
Fareva is looking for a Business Development Manager/Director for the Northern American market, based in NJ, NYC, and CT, to manage its injectables/ophthalmics/high potent businesses. The candidate should have at least 7 years of experience in technical sales in the pharmaceutical industry. Please visit www.fareva.com and contact Ed Saxman for further information at ESaxman@ho

Cancer Vaccines Market Will Soar to $7.5 Billion by 2022Cancer Vaccines Market Will Soar to $7.5 Billion by 2022
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth rate of 16.93%, according to business intelligence provider GBI Research.

Metrics: Stability Storage Facility Q&AMetrics: Stability Storage Facility Q&A
Metrics Contract Services recently announced it is investing $3.5 million to build a dedicated, 15,000-square-foot stability storage facility that will triple the organization’s current storage capacity. In a Q & A, Executive Vice President John S. Ross discusses the new facility and what it means to the organization.

Celyad's CAR-T Candidate Delivers in Early Stage Study Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion, dose escalation study evaluating the safety and feasibility of NKR-2 T-cells in Acute Myeloid Leukemia and Multiple Myeloma patients.
Market News & Trends
 



Copyright © 2016  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions